[New insights into intracellular inclusions and intracellular proteolysis].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Hauw JJ;Hauw JJ; Plu I; Seilhean D; Duyckaerts C
  • Source:
    Bulletin de l'Academie nationale de medecine [Bull Acad Natl Med] 2012 Nov; Vol. 196 (8), pp. 1575-85; discussion 1585-6.
  • Publication Type:
    Lecture
  • Language:
    French
  • Additional Information
    • Transliterated Title:
      Les inclusions intracellulaires sont-elles toujours des témoins d'un trouble de la protéolyse intracellulaire?
    • Source:
      Publisher: Académie nationale de médecine Country of Publication: Netherlands NLM ID: 7503383 Publication Model: Print Cited Medium: Print ISSN: 0001-4079 (Print) Linking ISSN: 00014079 NLM ISO Abbreviation: Bull Acad Natl Med Subsets: MEDLINE
    • Publication Information:
      Publication: Paris : Académie nationale de médecine
      Original Publication: Paris, Masson.
    • Subject Terms:
      Inclusion Bodies* ; Proteolysis*; Aging ; Humans ; Lipofuscin/physiology ; Neurodegenerative Diseases/etiology
    • Abstract:
      Intracellular inclusions seen by the pathologist may have variable significance. Although they are excellent markers of proteolytic disorders, they can also be due to several other mechanisms. This article examines recent data on the morphology, significance and consequences of aging lipofuscins in the brain and retina, neurofibrillary tangles and Lewy bodies, and Birbeck granules associated with Langerhans histiocytosis. Some of these disorders involve increased protein production, misfolding and aggregation, and altered intracellular proteolysis, but other cell constituents may also play a role. Proteolytic mechanisms do not appear to be involved in the formation of Birbeck granules, which helped to reveal the Langerhans origin of histiocytosis X. Analyses of intracellular inclusions, together with genetic and epigenetic studies, are highly informative in various degenerative diseases.
    • Accession Number:
      0 (Lipofuscin)
    • Publication Date:
      Date Created: 20131210 Date Completed: 20140109 Latest Revision: 20181202
    • Publication Date:
      20231215
    • Accession Number:
      24313013